5th Lipid Nanoparticles Development Summit Europe 2026

 

The 5th Lipid Nanoparticles Development Summit Europe returns to Berlin, 23–24 September 2026, as the leading meeting for advancing LNP-enabled gene therapy delivery.

Bringing together experts from BioNTech, AstraZeneca, Johnson & Johnson, Sanofi and AbbVie, the summit covers end-to-end LNP development, from formulation through to analytics, CMC and scalable manufacturing.

Attendees will explore solutions to overcome liver tropism, enable extrahepatic delivery and engineer next-generation nanoparticle systems across mRNA, DNA and gene editing therapies.

With interactive discussions and real-world case studies, this event delivers actionable insights to accelerate safe, targeted and clinically viable delivery platforms.

More Info

---

---